Estrella Immunopharma gets Nasdaq deficiency notice
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Estrella Immunopharma, Inc. (ESLA) reported receiving a notice from Nasdaq on September 1, 2026 that it no longer meets the Nasdaq Capital Market’s minimum $35,000,000 market value of listed securities requirement, after its MVLS stayed below that level for 30 consecutive business days.
Nasdaq also noted that the company does not meet the alternative standards for stockholders’ equity of at least $2,500,000 or net income of at least $500,000. ESLA has 180 calendar days, until March 1, 2027, to regain compliance by having MVLS at or above $35,000,000 for at least ten consecutive business days. Its common stock and warrants continue to trade on the Nasdaq Capital Market during this compliance period.
Positive
- None.
Negative
- Nasdaq non-compliance notice: ESLA’s market value of listed securities stayed below $35,000,000 for 30 consecutive business days, triggering a Nasdaq deficiency notice and creating a risk of potential delisting if compliance is not regained by March 1, 2027.
Filing Explained
The notice remains in its 180-day compliance period; if Estrella Immunopharma has not met the market-value test by
8-K Event Classification
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
1 item
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Key Figures
Minimum market value of listed securities (MVLS) requirement: $35,000,000
Deficiency measurement period: 30 business days
Compliance period length: 180 calendar days
+4 more
7 metrics
Minimum market value of listed securities (MVLS) requirement
$35,000,000
Required MVLS for continued listing on the Nasdaq Capital Market under Rule 5550(b)(2)
Deficiency measurement period
30 business days
MVLS was below $35,000,000 from July 21, 2026 through August 31, 2026
Compliance period length
180 calendar days
Time allowed to regain compliance, ending March 1, 2027
MVLS compliance trading requirement
10 business days
MVLS must be at or above $35,000,000 for at least ten consecutive business days
Alternative stockholders’ equity standard
$2,500,000
Minimum stockholders’ equity under Nasdaq Listing Rule 5550(b)(1), which ESLA does not meet
Alternative net income standard
$500,000
Required net income from continuing operations under Nasdaq Listing Rule 5550(b)(3), which ESLA does not meet
Compliance deadline
March 1, 2027
Date by which ESLA must regain compliance with the MVLS requirement
Key Terms
market value of the Company’s listed securities, Nasdaq Listing Rule 5550(b)(2), continued listing requirements, compliance period, +1 more
5 terms
market value of the Company’s listed securities financial
"because the market value of the Company’s listed securities (“MVLS”) was below"
Nasdaq Listing Rule 5550(b)(2) regulatory
"requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2)"
continued listing requirements regulatory
"subject to the Company’s compliance with the other continued listing requirements of Nasdaq"
Rules a stock exchange sets that a publicly traded company must keep meeting to stay listed and tradable on that exchange, such as minimum share price, market value, timely financial reports, and basic governance practices. Like a club’s membership rules, they matter because falling short can lead to warnings, penalties or removal from the exchange, which can cut liquidity, hurt share value and increase the risk for investors.
compliance period regulatory
"the Company has been provided a compliance period of 180 calendar days"
A compliance period is a defined stretch of time during which a company must meet specific legal, regulatory, or contractual rules and reporting requirements. Think of it like a scheduled inspection window or a homework deadline: failing to satisfy the rules within that window can trigger fines, restrictions, or extra oversight, so investors watch compliance periods as signals of near-term legal risk, potential costs, and impacts on a company’s operations or cash flow.
Nasdaq Capital Market market
"continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2)"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq deficiency did Estrella Immunopharma (ESLA) disclose?
ESLA disclosed a Nasdaq notice stating its market value of listed securities was below $35,000,000 for 30 consecutive business days through August 31, 2026, meaning it no longer meets the minimum MVLS requirement for continued listing on the Nasdaq Capital Market.
How long does ESLA have to regain Nasdaq listing compliance?
ESLA has 180 calendar days, until March 1, 2027, to regain compliance with the MVLS requirement. It must achieve a market value of listed securities of at least $35,000,000 for a minimum of ten consecutive business days within this period.
Does Estrella Immunopharma still meet Nasdaq’s alternative listing standards?
No. Nasdaq’s letter states ESLA does not meet the alternative continued listing standards of stockholders’ equity of at least $2,500,000 or net income from continuing operations of at least $500,000 in the most recent year or in two of the last three years.
Is ESLA’s stock being delisted from Nasdaq now?
No. The notice has no immediate effect on ESLA’s listing. Its common stock continues to trade on the Nasdaq Capital Market under the symbol “ESLA”, and its warrants under “ESLAW”, during the compliance period, subject to meeting other listing requirements.
What happens if ESLA fails to regain Nasdaq compliance by March 1, 2027?
If ESLA does not regain compliance by March 1, 2027, Nasdaq will issue a written notification that its securities are subject to delisting. ESLA would then have the right to appeal that determination to a Nasdaq hearings panel.
What actions does Estrella Immunopharma plan regarding the Nasdaq notice?
The company states that it intends to monitor its market value of listed securities and evaluate available options to regain compliance with the MVLS requirement. It also notes there is no assurance it will regain or maintain compliance.
AI-generated analysis. How Rhea-AI works. Not financial advice.
